David Canter to reveal plans for ex-Pfizer site's future in Ann Arbor at U-M event
Nathan Bomey | AnnArbor.com
Former Pfizer Ann Arbor site leader David Canter, who is managing the site's repositioning for U-M, will discuss the university's vision for the site over the next few years. He is speaking Friday morning at a symposium organized by U-M's A. Alfred Taubman Medical Research Institute and the Michigan Institute for Clinical & Health Research.
Canter's talk comes as the university is gradually making decisions about the site's future. AnnArbor.com first reported Sunday that the university plans to launch a business incubator to house some of its own startup companies at the former Pfizer site, now called North Campus Research Complex.
U-M's Technology Transfer Office and Business Engagement Center are moving at the end of September to a 32,000-square-foot space in a former Pfizer building at 1600 Huron Parkway, where they'll be clustered with the new incubator. U-M's Tech Transfer Office helped 10 startup companies spin out of the university during the 2009-10 fiscal year.
The university -- which recently agreed to lease 4,300 square feet of laboratory space at the site to an MSU spinoff company called BoroPharm -- plans to use the ex-Pfizer site to help strengthen its ties to commercial partners. It also wants to use the site to reconfigure its own research strategy. University administrators want researchers to work together in multi-disciplinary, cross-industry settings to produce technology breakthroughs.
Other speakers at Friday's event, called “Translational Research: The Bridge from Discovery to Medical Practice,” are U-M scientists Eva Feldman, Russell DeJong, Max Wicha and Blake Roessler.
"As research teams from around the university begin moving into the sprawling research campus, formerly owned by Pfizer, this year’s symposium is focusing on U-M’s commitment to translational research, transforming laboratory discoveries into real health gains through new approaches to prevention diagnosis and the treatment of disease," U-M said in a statement.